Alembic Pharma Q4 profit falls 12%, revenue rises 17%

AHMEDABAD: Alembic Pharmaceuticals reported a 12.1% year-on-year drop in consolidated net profit to Rs 156.63 crore for the quarter ended 31 March 2025, despite a 16.7% rise in revenue from operations to Rs 1,769.64 crore. The company’s profit before tax increased 5% to Rs 191.95 crore, while EBITDA rose 9% to Rs 266 crore, with margins steady at 16%.

The India formulations business grew 8% to Rs 545 crore, led by strong performance in Gynaecology, Anti-Diabetic, and Dermatology therapies. US revenue climbed 20% to Rs 508 crore, aided by four launches, while Ex-US markets posted a robust 43% growth to Rs 375 crore. API revenue rose modestly by 4% to Rs 342 crore.
For the full year FY25, consolidated revenue rose 7% to Rs 6,672 crore.

Despite the Q4 profit decline, Alembic Pharma MD, Shaunak Amin, said, “The company remains well-positioned for sustained growth, citing strong execution across domestic, international, and animal health segments.”

Shares of Alembic Pharmaceuticals closed 2.46% lower at Rs 881.65 on the BSE following the earnings announcement.